Coronary Artery Disease, Coronary Occlusion, Coronary Stenosis
Conditions
Keywords
Registry, Percutaneous coronary interventions, Coronary artery disease
Brief summary
This registry aims to learn more about the best ways to treat coronary artery disease. Information from routine medical care will be collected to compare different treatment approaches, including drug-eluting stents, drug-coated balloons (DCB), and bioresorbable scaffolds (BRS), which gradually dissolve over time. The registry will include people with coronary artery disease who receive an intervention (percutaneous coronary intervention), including those undergoing more complex procedures. By studying treatment outcomes over time, the Registry aims to better understand which therapies work best for different groups of patients and to improve future care for people with coronary artery disease.
Detailed description
The PCI Registry Basel is established to systematically collect real-world data on all patients (≥18 years) undergoing percutaneous coronary interventions (PCI) at the University Hospital Basel. The primary purpose of the registry is to investigate the best treatment strategies in patients with coronary artery disease (CAD) and their associated outcomes in routine clinical practice, including complex procedures (e.g. chronic total occlusions (CTO), bifurcation lesions, left main interventions), the use of drug-coated balloons (DCB) and bioresorbable scaffolds (BRS), as well as standard drug-eluting stent (DES) implantation. Data are derived retrospectively from routine clinical practice at the University Hospital Basel. Relevant procedural, clinical, and follow-up information is extracted from existing sources such as the catheterization lab reports, and the electronic health record (Cardioapp). No additional data collection or invasive study-specific interventions are performed for the purpose of this registry. Where applicable, data from previous research projects or registries may also be incorporated, provided that all legal and ethical requirements are satisfied. All data will be pseudonymised before analysis. A secure decoding key linking registry numbers to patient identifiers is kept separately and is accessible only to authorized personnel under the responsibility of the Principal Investigator.
Interventions
None listed
Sponsors
University Hospital, Basel, Switzerland
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients treated at the University Hospital Basel * Undergoing complex PCI (e.g. left main, bifurcation, multivessel PCI, rotational atherectomy or other calcium modification, complex anatomy). The definition complex will be a clinical/ procedural/ anatomical definition made by the operator. * Undergoing CTO or CHIP (Complex High-risk Indicated Patient) procedures * Treated with a DCB strategy * Treated with a BRS
Exclusion criteria
* Patients under 18 years of age
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Target Vessel Failure (TVF) | Through study completion, an average of 1 year | Composite endpoint defined as the occurrence of cardiovascular death, target vessel myocardial infarction, or unplanned target vessel revascularisation. |
Countries
Switzerland
Contacts
CONTACTGregor Leibundgut, Prof. Dr. med.
CONTACTJasper Boeddinghaus, PD Dr. med.
PRINCIPAL_INVESTIGATORGregor Leibundgut, Prof. Dr. med.
University Hospital, Basel, Switzerland
PRINCIPAL_INVESTIGATORJasper Boeddinghaus, PD Dr. med.
University Hospital, Basel, Switzerland
Outcome results
None listed